Ocular Therapeutix

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Ocular Therapeutix 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About OCUL

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. 

CEO
Pravin U. Dugel
CEOPravin U. Dugel
Employees
325
Employees325
Headquarters
Bedford, Massachusetts
HeadquartersBedford, Massachusetts
Founded
2006
Founded2006
Employees
325
Employees325

OCUL Key Statistics

Market cap
2.11B
Market cap2.11B
Price-Earnings ratio
-6.75
Price-Earnings ratio-6.75
Dividend yield
Dividend yield
Average volume
2.71M
Average volume2.71M
High today
High today
Low today
Low today
Open price
$9.38
Open price$9.38
Volume
222.00
Volume222.00
52 Week high
$16.44
52 Week high$16.44
52 Week low
$6.23
52 Week low$6.23

Stock Snapshot

With a market cap of 2.11B, Ocular Therapeutix(OCUL) trades at $9.94. The stock has a price-to-earnings ratio of -6.75.

On 2026-05-06, Ocular Therapeutix(OCUL) shares started trading at $9.38, with intraday highs of — and lows of —.

Trading activity shows a volume of 222, compared to an average daily volume of 2.71M.

The stock's 52-week range extends from a low of $6.23 to a high of $16.44.

The stock's 52-week range extends from a low of $6.23 to a high of $16.44.

OCUL News

TipRanks 16h
Analyst Reiterates Buy Rating on OCUL, Keeps Axpaxli-Driven Price Target Unchanged at $18

Analyst Serge Belanger from Needham maintained a Buy rating on Ocular Therapeutix and keeping the price target at $18.00. Unlock hedge fund-level data and powe...

TipRanks 1d
Ocular Therapeutix reports Q1 EPS (40c), consensus (31c)

Reports Q1 revenue $10.79M, consensus $12.7M. “2026 is off to a tremendous start for Ocular, driven by the superiority demonstrated with AXPAXLI in the landmark...

Analyst ratings

100%

of 12 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own OCUL. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.